<DOC>
	<DOCNO>NCT00060333</DOCNO>
	<brief_summary>This phase II trial study well adjuvant radiation therapy work treat patient undergone surgery desmoplastic melanoma . Radiation therapy use high-energy x-rays damage tumor cell . Giving radiation therapy surgery may kill tumor cell remain surgery .</brief_summary>
	<brief_title>Adjuvant Radiation Therapy Treating Patients With Resected Desmoplastic Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess recurrence rate patient desmoplastic melanoma ( DM ) &gt; = 1 mm deep treat adjuvant radiotherapy surgical resection . II . Assess recurrence rate patient locally recurrent DM treat adjuvant radiotherapy surgical resection . SECONDARY OBJECTIVES : I . Evaluate impact adjuvant radiation therapy surgical resection disease free overall survival . II . Evaluate immediate long-term morbidity addition radiotherapy surgery . OUTLINE : Within 8 week surgical resection , patient undergo radiation therapy twice weekly approximately 2.5 week total 5 fraction absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion Criteria Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Pathologically proven DM &gt; = 1 mm depth locally recurrent DM ; recurrent tumor define tumor find = &lt; 2 cm previous excision within surgical bed ( include extent previous skin flap ) DM resect pathologically negative margin ; acceptable surgery include standard wide local excision Moh 's surgery Tumors trunk proximal extremity need &gt; = 2 cm negative margin ; tumor locate head neck distal extremity attempt 2 cm negative margin due location subsequent concern regard cosmesis margin &lt; 2 cm acceptable margin negative Margins tumor resect use Moh 's technique accept negative best approximation tumor width make Radiation therapy ( RT ) begin = &lt; 8 week definitive surgical resection Adjuvant systemic therapy ( immunotherapy chemotherapy ) must postpone irradiation complete Exclusion Criteria Previous irradiation site Nonhealing surgical wind Active infection surgical site Evidence metastatic disease ; local nodal disease still eligible trial Life expectancy &lt; 1 year Melanoma focally desmoplastic feature , desmoplastic melanoma predominant histologic pattern tumor , exclude ; nondesmoplastic neurotropic melanoma nondesmoplastic spindle cell melanoma also exclude Previous malignancy &lt; 5 year exclude basal cell carcinoma squamous cell carcinoma skin cervical carcinoma situ ( exception patient stage I breast cancer adequately treat adjuvant therapy currently disease free , patient stage I II prostate cancer treat prostatectomy radiotherapy biochemically free disease [ radical retropubic prostatectomy ( RRP ) prostatespecific antigen ( PSA ) &lt; 0.3 radiotherapy PSA &lt; 2.0 post treatment nadir ] ) Any follow : Pregnant woman Women childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage I melanoma</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
</DOC>